Thirty percent of surveyed women with breast cancer reported skipping additional treatment following surgery.
The implication: these women were irrational.
Although the research paper was released in November, these women were diagnosed with cancer a decade ago, 2005-2007, and the data were collected almost a decade ago, 2007-2009.
Perhaps the most egregious part of this research is that it treats “breast cancer” as a singular disease rather than the extremely heterogenous entity that it is. And how relevant are the findings to today’s patient given the age of the data?
Continue reading “Were these women irrational when they rejected adjuvant breast cancer treatment?”
Invasive lobular cancer represents 5-15 percent of all breast cancers (depending on the study). Although it is distinctly different and responds differently to therapy, it has been treated exactly like ductal cancer for decades.
Continue reading “Crowdsourcing database of lobular breast cancer research”
A British research study followed more than 2,000 women for five years has found that targeting the tumor site, rather than the entire breast, was just as effective for women with early stage ductal breast cancer.
The results (open data) were published in The Lancet.
Continue reading “British study suggests reduced radiation effective for early stage ductal breast cancer”
The research goal was to compare of the metastatic pattern of invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) at both first distant recurrence (FDR) as well as over the entire course of metastatic disease.
Continue reading “Distinct pattern of metastases in patients with invasive lobular carcinoma of the breast”
Invasive lobular carcinoma (ILC) is the second most common subtype of breast cancer; ILC differs from invasive ductal carcinoma (IDC) both in clinicopathological characteristics and responsiveness to systemic therapy.
Continue reading “Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications”